. 2021 May 7;10(1):143.

doi: 10.1186/s13643-021-01693-7.

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Benjamin P Geisler^{1

2}, Lara Zahabi³, Adam Edward Lang⁴, Naomi Eastwood⁵, Elaine Tennant^{6

7}, Ljiljana Lukic⁸, Elad Sharon⁹, Hai-Hua Chuang^{10

11

12}, Chang-Berm Kang¹³, Knakita Clayton-Johnson¹⁴, Ahmed Aljaberi¹⁵, Haining Yu¹⁶, Chinh Bui¹⁷, Tuan Le Mau¹⁸, Wen-Cheng Li¹⁰, Debbie Teodorescu^{19

17}, Ludwig Christian Hinske²⁰, Dennis L Sun²¹, Farrin A Manian¹⁹, Adam G Dunn²²

Affiliations

¹ Ludwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany. bgeisler@post.harvard.edu.
² Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. bgeisler@post.harvard.edu.
³ McGill University, Montreal, Canada.
⁴ McDonald Army Health Center, Fort Eustis, VA, USA.
⁵ Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
⁶ Royal North Shore Hospital, Sydney, NSW, Australia.
⁷ University of New South Wales, Sydney, NSW, Australia.
⁸ University Hospital for Infectious Disease Zagreb "Dr. Fran Mihaljevic", Zagreb, Croatia.
⁹ National Cancer Institute, Bethesda, MD, USA.
¹⁰ Chang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan.
¹¹ National Taipei University of Technology, Taipei, Taiwan.
¹² Geisinger Medical Center, Danville, PA, USA.
¹³ Proof Biotechnologies, Inc., Columbia, SC, USA.
¹⁴ Portmore Hospital Complex, Portmore, Jamaica.
¹⁵ Brigham and Women's Hospital, Boston, MA, USA.
¹⁶ University of California San Francisco Medical Center, San Francisco, CA, USA.
¹⁷ Massachusetts Institute for Technology, Cambridge, MA, USA.
¹⁸ Institute of High Performance Computing, Singapore, Singapore.
¹⁹ Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
²⁰ Ludwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany.
²¹ California Polytechnic State University, San Luis Obispo, CA, USA.
²² University of Sydney, Sydney, NSW, Australia.

PMID: 33962652
PMCID: PMC8103882
DOI: 10.1186/s13643-021-01693-7

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Benjamin P Geisler et al. Syst Rev. 2021.

. 2021 May 7;10(1):143.

doi: 10.1186/s13643-021-01693-7.

Authors

Affiliations

¹ Ludwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany. bgeisler@post.harvard.edu.
² Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA. bgeisler@post.harvard.edu.
³ McGill University, Montreal, Canada.
⁴ McDonald Army Health Center, Fort Eustis, VA, USA.
⁵ Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.
⁶ Royal North Shore Hospital, Sydney, NSW, Australia.
⁷ University of New South Wales, Sydney, NSW, Australia.
⁸ University Hospital for Infectious Disease Zagreb "Dr. Fran Mihaljevic", Zagreb, Croatia.
⁹ National Cancer Institute, Bethesda, MD, USA.
¹⁰ Chang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan.
¹¹ National Taipei University of Technology, Taipei, Taiwan.
¹² Geisinger Medical Center, Danville, PA, USA.
¹³ Proof Biotechnologies, Inc., Columbia, SC, USA.
¹⁴ Portmore Hospital Complex, Portmore, Jamaica.
¹⁵ Brigham and Women's Hospital, Boston, MA, USA.
¹⁶ University of California San Francisco Medical Center, San Francisco, CA, USA.
¹⁷ Massachusetts Institute for Technology, Cambridge, MA, USA.
¹⁸ Institute of High Performance Computing, Singapore, Singapore.
¹⁹ Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
²⁰ Ludwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany.
²¹ California Polytechnic State University, San Luis Obispo, CA, USA.
²² University of Sydney, Sydney, NSW, Australia.

PMID: 33962652
PMCID: PMC8103882
DOI: 10.1186/s13643-021-01693-7

Abstract

Background: Coronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19.

Methods: This systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence.

Discussion: The challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review.

Trial registration: PROSPERO 2020 CRD42020175648.

Keywords: COVID-19; MERS-CoV; Middle East respiratory syndrome Coronavirus; Repurposed; Repurposing; SARS; SARS-CoV2; Severe acute respiratory syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Update of

Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review.
Geisler BP, Zahabi L, Lang AE, Eastwood N, Tennant E, Lukic L, Sharon E, Chuang HH, Kang CB, Clayton-Johnson K, Aljaberi A, Yu H, Bui C, Mau TL, Li WC, Teodorescu D, Hinske LC, Sun DL, Manian FA, Dunn AG. Geisler BP, et al. medRxiv [Preprint]. 2020 May 23:2020.05.21.20109074. doi: 10.1101/2020.05.21.20109074. medRxiv. 2020. Update in: Syst Rev. 2021 May 7;10(1):143. doi: 10.1186/s13643-021-01693-7. PMID: 32511471 Free PMC article. Updated. Preprint.

References

1. Barro RJ, Ursúa JF, Weng J. The coronavirus and the great influenza pandemic: lessons from the “Spanish flu” for the coronavirus’s potential effects on mortality and economic activity. Cambridge: National Bureau of Economic Research; 2020.
1. He D, Zhao S, Li Y, Zhuang Z, Cao P, Gao D, Lou Y, Yang L. History is the best model–a comparison of the COVID-19 with the 1918-19 pandemic influenza in United Kingdom. 2020.
1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi: 10.1016/S0140-6736(20)31022-9. - DOI - PMC - PubMed
1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members Remdesivir for the treatment of Covid-19 — preliminary report. New England J Med. 2020;383(19):1813–1826. doi: 10.1056/NEJMoa2007764. - DOI - PMC - PubMed
1. Mohs RC, Greig NH. Drug discovery and development: role of basic biological research. Alzheimers Dement (N Y) 2017;3(4):651–657. doi: 10.1016/j.trci.2017.10.005. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Affiliations

Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Authors

Affiliations

Abstract

Conflict of interest statement

Update of

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous